Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with Cystic Fibrosis.

Status

Withdrawn

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000053527

Enrollment

Registered

2006-02-07

Start date

2006-02-10

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

4mL of 6% saline delivered via an eFlow nebuliser four times daily for 2 weeks.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Healthy volunteers

Inclusion criteria

Cystic fibrosis, member of RPA Hospital CF Clinic, stable clinical condition (no non-routine antibiotics in the previous 2 weeks), FEV1 >40% pred.

Exclusion criteria

Unable/unwilling to provide informed consent, major haemoptysis in the previous year, pregnant or lactating, investigational drugs in the previous 30 days. There is no age limit.

Outcome results